Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Carfilzomib for Inj 60 milligram · 1 trial · 1 indication
The proportion of patients having achieved at least partial response.
| Arm | Type | Description |
|---|---|---|
| Carfilzomib, elotuzumab, dexamethasone | EXPERIMENTAL | Carfilzomib 70 milligram(mg)/m2 iv (56 mg/m2 for first five patients for cycles 1-2) once weekly, on days 1, 8 and 15 (cycles 1-8), from cycle 9 on days 1 and 15 until progression or toxicity; elotuzumab 10 mg/kg iv on days 1,8,15 for cycles 1-2, on days 1and 15 from cycle 3 until progression or toxicity; dexamethasone 40 mg weekly (shared to po and iv) |
| Name | Type | Description |
|---|---|---|
| Carfilzomib for Inj 60 milligram (MG) | DRUG | All patients will have similar effective study drug combination; karfilzomib plus elotuzumab plus dexamethasone |
| Elotuzumab 400 MG | DRUG | All patients will have similar effective study drug combination; karfilzomib plus elotuzumab plus dexamethasone |
| Dexamethasone | DRUG | All patients will have similar effective study drug combination; karfilzomib plus elotuzumab plus dexamethasone |
Inclusion Criteria: 1. Male or female patients at the age of 18 to below 75 years with the life expectancy of at least three months. 2. Prior confirmed diagnosis of multiple myeloma and measurable disease in blood or urine with at least one of the following: Serum M-protein ≥ 5g/l, Urine M-protein ...